| 영문 | epidemic parotitis, mumps | 한글 | 볼거리, 유행귀밑샘염 |
|---|---|---|---|
| 설명 | 주로 소아에서 일어나고, 그 결과로 지속성 면역을 주는 전염성의 paramyxovirus 병. 흡기에 의해서 감염되는데, 가장 농후한 바이러스감염은 침샘내에 생기며, 특히 턱밑샘이나 혀밑샘보다도 귀밑샘이 더욱 심하다. 잠복기는 18~22일이다. 감염은 약 75%의 증례에서 증상을 나타낸다. 이들 중 귀밑샘염은 70%에서, 수막염은 10~15%(이들 중 반수에서 무증상성 수액세포 증가증이 동반된다)에서 일어난다. 부고환고환염이 사춘기 후의 남성에서 생기지만 그 후에 불임증을 속발하는 일은 드물다. 그 외의 증상은 보다 드물게 나타나는데 이자염, 관절염, 심근염, 난소염, 갑상샘염 및 젖샘염 등이 있다. 발열과 환부의 유통성 염증은 최초의 2일간에 가장 현저하고 다음 4~5일이 지나면 서서히 가라앉는다. 동시에 한 부위 이상을 침습하는 수도 있으며 가끔 속발적으로 침습되고 질환의 전 경과는 2~3주에 이른다. 부수되는 영속성의 신경학적 손상을 동반하는 수막뇌염은 드물다. |
||
| 영문 | carcinoembryonic antigen | 한글 | 암배아항원 |
|---|---|---|---|
| 설명 | 원래 태아의 장조직에서 정상적으로 존재하는 물질로 태아기 이후에는 존재하지 않는 물질이다. 그러나 위, 간, 허파 등의 암이 있는 경우에 성인에서도 존재한다. 이를 이용해서 암의 치료효과 판정이나 재발여부의 조사에 이용한다. |
||
| 영문 | antigen | 한글 | 항원 |
|---|---|---|---|
| 설명 | 특이한 면역반응을 일으킬 수 있는 어떠한 물질. 여기에서 말하는 특이한 면역반응이란 비특이적인 면역반응과는 반대되는 의미로 그 물질에 대해서 특이하게 반응할 수 있는 항체나 그 물질에 대해서 특이하게 반응할 수 있는 세포를 만드는 것을 말한다. |
||
| 영문 | basal layer of skin | 한글 | 기저층 |
|---|---|---|---|
| 설명 | 표피의 가장 아래 부분이며 세포의 모양이 비교적 직사각형에 가깝고 일정한 배열을 한다. |
||
| 영문 | skin tag | 한글 | 쥐젖, 피부연성섬유종 |
|---|---|---|---|
| 설명 | 주로 목, 겨드랑이, 다리에 생기는 살색 또는 과색소 침착성의 작은 목을 가진 섬유성 돌출물로 대개 무증상이다. |
||
| ST | esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor... |
|---|---|
| TSTA | toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen... |
| STD | selective T-cell defect; sexually transmitted disease; skin-to-tumor distance; skin test dose; sodiu... |
| PAT | Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili... |
| HLA | histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod... |
| MMR | MEASLES: mumps-rubella |
|---|---|
| MMR | Measles, mumps and rubella |
| MMR | Measles-Mumps-Rubella vaccine |
| MuV | Mumps virus |
| IDST | intradermal skin test |
| mumps skin test antigen | A sterile suspension of killed mumps virus in isotonic sodium chloride solution, used to determine susceptibility to mumps or to confirm previous exposure. (05 Mar 2000) |
|---|
| aspergillus antigen skin test | <investigation> An antigen, prepared from aspergillus, is injected into the skin. In 48 to 72 hours the site is read as positive or negative. A positive skin test (inflammation at the test site) indicates prior exposure to aspergillus and therefore a risk for developing aspergillosis. (27 Sep 1997) |
|---|---|
| mumps sensitivity test | A skin test for sensitivity to mumps, in which inactivated mumps virus is used as antigen. (05 Mar 2000) |
| vaccination, mumps | See Vaccination, MMR. Vaccination, pneumococcal pneumonia: this vaccine, which prevents one of the most common and severe forms of pneumonia, is usually given only once in a lifetime, usually after the age of 55, to someone with ongoing lung problems (such as chronic obstructive pulmonary disease (copd) or asthma) or other chronic diseases (including those involving the heart and kidneys). This vaccination would rarely be given to children. (12 Dec 1998) |
| measles, mumps and rubella vaccine | A combination of live attenuated measles, mumps, and rubella viruses in an aqueous suspension; used for immunization against the respective diseases. (05 Mar 2000) |
| metastatic mumps | Mumps complicated by involvement of organs other than parotid glands, such as the testis, breast, or pancreas. (05 Mar 2000) |
| mumps | An infectious acute viral disease affecting the parotid glands. The gonads, meninges and pancreas can also be affected. The causative agent is a paramyxovirus. Humans are the only natural host for this disease. Common symptoms include weakness, fever, sore throat, malaise and puffiness to the cheeks (due to parotid gland swelling). Patients are contagious 1 day prior to the onset of swelling until the swelling is gone. Recovery is generally in 2 weeks. (27 Sep 1997) |
| mumps immunization | The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination. (12 Dec 1998) |
| mumps in pregnancy | It has been stated, we believe erroneously, that mumps is dangerous when contracted during pregnancy. For example, vetter (infect med 14:730-733, 1997), citing a single 1980 article, writes: mumps infection during the first trimester of pregnancy can increase the rate of spontaneous abortion. Congenital anomalies associated with mumps infection during pregnancy include endocardial fibroelastosis; imperforate anus; spina bifida; and auditory, optic, and urogenital deformities. However, shepard in his authorative catalog of teratogenic agents (j hopkins u press, 8th edition, 1995) does not consider that mumps merits inclusion as a proven or even possible teratogenic agent, that is as an agent capable of causing a spontaneous abortion (a miscarriage) or causing congenital malformations (the baby is born with birth defects). Furthermore, mumps does not even warrant mention in smith's recognizable patterns of human malformation (by kl jones, wb saunders co., 5th edition, 1997), a key standard text on dysmorphology (the study of malformations). Based also on our review of the facts available at this time (oct, 1997), we conclude that there is insufficient evidence to label mumps as a particular hazard in pregnancy. (12 Dec 1998) |
| mumps meningoencephalitis | A usually benign nervous system infection arising during the active phase of clinical mumps parotiditis. (05 Mar 2000) |
| mumps orchitis | <pathology> A mumps infection that has affected the testicles. Approximately 20-35% of postpubertal males with mumps will develop this complication. (27 Sep 1997) |
| mumps vaccine | A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunised with live mumps vaccine. Children are usually immunised with measles-mumps-rubella combinatiom vaccine. (12 Dec 1998) |
| mumps virus | The type species of rubulavirus that causes an acute infectious disease in humans, affecting mainly children. Transmission occurs by droplet infection. (12 Dec 1998) |
| mumps virus vaccine | Vaccine containing live, attenuated mumps virus prepared in chick embryo cell cultures. See: measles, mumps, and rubella vaccine. (05 Mar 2000) |
| immunization, mumps | See Immunization, MMR. (12 Dec 1998) |
| allergy skin test | Test done on the skin to identify the allergy substance (allergen) triggering the allergic reaction. A small amount of the suspected allergy substance is placed on the skin. The skin is then gently scratched through the small drop with a special sterile needle. If the skin reddens and, more importantly, swells, then allergy to that substance is probable. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|